Trial Profile
A MULTICENTRE, SINGLE-ARM, OPEN-LABEL STUDY TO CHARACTERISE THE RELATIONSHIP BETWEEN PRE-TRANSPLANT PHARMACOKINETICS OF ADVAGRAF AND THE DOSE REQUIRED POST-TRANSPLANT TO ACHIEVE TARGET TROUGH LEVELS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2019
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Pharmacokinetics
- Acronyms PREDICT
- Sponsors Astellas Pharma Europe Ltd
- 14 Dec 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 19 Nov 2013 New trial record